Corresponding Author: Catherine Y. Liu, MD, PhD, Division of Oculofacial Plastic and Reconstructive Surgery, Shiley Eye Institute, University of California, San Diego, 9415 Campus Point Dr, La Jolla, CA 92093 (yul107@health.ucsd.edu).
Published Online: July 7, 2022. doi:10.1001/jamaophthalmol.2022.1541
Conflict of Interest Disclosures: Dr Liu reported a research grant from Horizon Therapeutics and royalties from Wolters Kluwer Health outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank the patient’s family for granting permission to publish this information.
1.Cho
YJ , Kwon
H , Kwon
YJ , Kim
SC , Kim
DY , Namgoong
JM . Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: a single-center experience.
J Vasc Surg Venous Lymphat Disord. 2021;9(6):1488-1494. doi:
10.1016/j.jvsv.2021.03.014
PubMedGoogle ScholarCrossref 3.Dávila-Osorio
VL , Iznardo
H , Roé
E , Puig
L , Baselga
E . Propranolol-resistant infantile hemangioma successfully treated with sirolimus.
Pediatr Dermatol. 2020;37(4):684-686. doi:
10.1111/pde.14163
PubMedGoogle ScholarCrossref 5.Hutchins
KK , Ross
RD , Kobayashi
D , Martin
A , Rajpurkar
M . Treatment of refractory infantile hemangiomas and pulmonary hypertension with sirolimus in a pediatric patient.
J Pediatr Hematol Oncol. 2017;39(7):e391-e393. doi:
10.1097/MPH.0000000000000961
PubMedGoogle ScholarCrossref 7.Krowchuk
DP , Frieden
IJ , Mancini
AJ ,
et al; Subcommittee on the Management of Infantile Hemangiomas. Clinical practice guideline for the management of infantile hemangiomas.
Pediatrics. 2019;143(1):e20183475. doi:
10.1542/peds.2018-3475
PubMedGoogle ScholarCrossref